GEHC Ebitda from 2010 to 2024

GEHC Stock   82.79  0.43  0.52%   
GE HealthCare's EBITDA is increasing over the years with very volatile fluctuation. Overall, EBITDA is expected to go to about 2.5 B this year. During the period from 2010 to 2024 GE HealthCare EBITDA annual values regression line had geometric mean of  2,879,357,456 and mean square error of 90596.1 T. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
2.4 B
Current Value
2.5 B
Quarterly Volatility
290.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GE HealthCare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GE HealthCare's main balance sheet or income statement drivers, such as Tax Provision of 653 M, Interest Income of 29 M or Discontinued Operations of 15.4 M, as well as many indicators such as Price To Sales Ratio of 1.29, Dividend Yield of 9.0E-4 or PTB Ratio of 5.18. GEHC financial statements analysis is a perfect complement when working with GE HealthCare Valuation or Volatility modules.
  
Check out the analysis of GE HealthCare Correlation against competitors.

Latest GE HealthCare's Ebitda Growth Pattern

Below is the plot of the Ebitda of GE HealthCare Technologies over the last few years. It is GE HealthCare's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GE HealthCare's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Very volatile
   Ebitda   
       Timeline  

GEHC Ebitda Regression Statistics

Arithmetic Mean2,892,496,000
Geometric Mean2,879,357,456
Coefficient Of Variation10.05
Mean Deviation191,134,933
Median2,838,000,000
Standard Deviation290,567,944
Sample Variance84429.7T
Range1.1B
R-Value0.06
Mean Square Error90596.1T
R-Squared0
Significance0.83
Slope3,903,857
Total Sum of Squares1182016.2T

GEHC Ebitda History

20242.5 B
20232.4 B
20223.2 B
20213.5 B
20203.4 B

About GE HealthCare Financial Statements

GE HealthCare stakeholders use historical fundamental indicators, such as GE HealthCare's Ebitda, to determine how well the company is positioned to perform in the future. Although GE HealthCare investors may analyze each financial statement separately, they are all interrelated. For example, changes in GE HealthCare's assets and liabilities are reflected in the revenues and expenses on GE HealthCare's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in GE HealthCare Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA2.4 B2.5 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether GE HealthCare Techno offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GE HealthCare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ge Healthcare Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ge Healthcare Technologies Stock:
Check out the analysis of GE HealthCare Correlation against competitors.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GE HealthCare. If investors know GEHC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GE HealthCare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.242
Dividend Share
0.12
Earnings Share
3.65
Revenue Per Share
42.916
Quarterly Revenue Growth
0.009
The market value of GE HealthCare Techno is measured differently than its book value, which is the value of GEHC that is recorded on the company's balance sheet. Investors also form their own opinion of GE HealthCare's value that differs from its market value or its book value, called intrinsic value, which is GE HealthCare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GE HealthCare's market value can be influenced by many factors that don't directly affect GE HealthCare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GE HealthCare's value and its price as these two are different measures arrived at by different means. Investors typically determine if GE HealthCare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GE HealthCare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.